克隆调节抗糖尿病代谢效应的阿迪波涅克丁受体
Toshimasa Yamauchi1, Junji Kamon, Yusuke Ito
1Department of Internal Medicine, Graduate School of Medicine, University of Tokyo, Tokyo 113-8655, Japan.
Nature
|June 13, 2003
概括
研究人员确定了两种新的阿迪波涅克丁受体,AdiporoR1和AdiporoR2,它们对于调解阿迪波涅克丁降糖和胰岛素敏感作用至关重要. 这些受体是理解和潜在治疗糖尿病等代谢障碍的关键.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 代谢研究研究 代谢研究
背景情况:
- 阿迪波内克丁是一种具有抗糖尿病和抗原性质的阿迪波金.
- 降低阿迪波涅丁水平与肥胖,胰岛素抵抗和2型糖尿病有关.
- 在临床前模型中,阿迪波内克丁的使用改善了胰岛素敏感性和葡萄糖代谢.
研究的目的:
- 为了识别和克隆编码阿迪波内克丁受体的互补DNA.
- 描述这些新型受体的表达模式和功能角色.
- 为了阐明底层的分子机制阿迪波内克丁的代谢作用.
主要方法:
- 表达式克隆被用来识别胺素受体.
- 克隆了编码AdipoR1和AdipoR2的互补DNA.
- 用小干扰RNA来抑制受体表达并评估功能后果.
主要成果:
- 已经成功克隆了两个阿迪波尼克丁受体,AdiporoR1和AdiporoR2.
- 阿迪波R1主要表达在骨肌肉中,而阿迪波R2主要存在于肝脏中.
- 这些受体调解阿迪波内克丁对AMP激酶和PPAR-alpha激活,脂肪酸氧化和葡萄糖吸收的影响.
结论:
- 阿迪波R1和阿迪波R2是阿迪波内克丁的主要受体.
- 这些受体对阿迪波内克丁的胰岛素敏感性和降糖作用至关重要.
- 这些受体的识别为代谢疾病的治疗干预开辟了新的途径.
更多相关视频
相关概念视频
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Spare Receptors
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...


